Antje Hoering

Experimental Design & Analysis of Protein Array Data: Applying Methods from cDNA Arrays.

Jeanette E. Eckel, Antje Hoering, Irene M. Ghobrial, 2004 .

Exploratory and High-Dimensional Data Analyses

Antje Hoering, John Crowley, 2012 .

Clustering or Automatic Class Discovery: Hierarchical Methods

Derek C. Stanford, Antje Hoering, Douglas B. Clarkson, 2003 .

On the analysis of viral load endpoints in HIV vaccine trials

Michael G Hudgens, Antje Hoering, Steven G Self, 2003, Statistics in medicine.

Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528

Razelle Kurzrock, Antje Hoering, Vincent Chung, 2013, Cancer Chemotherapy and Pharmacology.

Seamless Phase I-II Trial Design for Assessing Toxicity and Efficacy for Targeted Agents

Antje Hoering, M. LeBlanc, J. Crowley, 2010, Clinical Cancer Research.

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

Pingping Qu, Fadi Towfic, Konstantinos Mavrommatis, 2018, Leukemia.

1 Identification of Novel Mutational Drivers Reveals Oncogene Dependencies In Multiple Myeloma . Short title : Oncogene dependencies in myeloma

Pingping Qu, Fadi Towfic, Konstantinos Mavrommatis, 2018 .

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia

Robert K. Stuart, Antje Hoering, Arthur C. Louie, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized Phase III Clinical Trial Designs for Targeted Agents

Antje Hoering, M. LeBlanc, J. Crowley, 2008, Clinical Cancer Research.

The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma

Pingping Qu, Bart Barlogie, Antje Hoering, 2017, Haematologica.

Early phase trial design for assessing several dose levels for toxicity and efficacy for targeted agents

Antje Hoering, Michael LeBlanc, Alan Mitchell, 2013, Clinical trials.